USP17L2 and ovarian cancer: Collectively, these results demonstrate that the dysregulated CK2α-DUB3-YAP1 axis contributes to the tumor progression of ovarian cancer and the therapeutic strategies targeting this axis could be of benefit in the clinical management of ovarian cancer.